Technical Analysis for BXRX - Baudax Bio, Inc.

Grade Last Price % Change Price Change
F 1.2 -7.69% -0.10
BXRX closed down 7.69 percent on Thursday, March 4, 2021, on 78 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical BXRX trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.42%
Down 3 Days in a Row Weakness 0.42%
Lower Bollinger Band Touch Weakness 0.42%
Oversold Stochastic Weakness 0.42%
50 DMA Resistance Bearish -7.69%
Wide Bands Range Expansion -7.69%
Oversold Stochastic Weakness -7.69%
Fell Below 50 DMA Bearish -11.11%
MACD Bearish Centerline Cross Bearish -11.11%
180 Bearish Setup Bearish Swing Setup -11.11%
Older End-of-Day Signals for BXRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Lower Bollinger Band Support about 9 hours ago
1.5x Volume Pace about 10 hours ago
Fell Below Lower Bollinger Band about 10 hours ago
Down 10% about 10 hours ago
Down 5% about 10 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Baudax Bio, Inc. Description

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.


Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Drugs Clinical Trial Opioid Psychoactive Drugs Euphoriants Analgesics Orthopedic Surgery Neurochemistry Ketones Anxiolytics Colorectal Surgery Dexmedetomidine

Is BXRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 6.1791
52 Week Low 0.1
Average Volume 6,813,581
200-Day Moving Average 2.41
50-Day Moving Average 1.37
20-Day Moving Average 1.59
10-Day Moving Average 1.42
Average True Range 0.18
ADX 21.22
+DI 16.78
-DI 29.96
Chandelier Exit (Long, 3 ATRs ) 1.59
Chandelier Exit (Short, 3 ATRs ) 1.68
Upper Bollinger Band 2.02
Lower Bollinger Band 1.16
Percent B (%b) 0.05
BandWidth 54.45
MACD Line -0.04
MACD Signal Line 0.02
MACD Histogram -0.0613
Fundamentals Value
Market Cap 34.91 Million
Num Shares 29.1 Million
EPS -3.59
Price-to-Earnings (P/E) Ratio -0.33
Price-to-Sales 51.11
Price-to-Book 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.40
Resistance 3 (R3) 1.40 1.34 1.36
Resistance 2 (R2) 1.34 1.29 1.34 1.35
Resistance 1 (R1) 1.27 1.26 1.24 1.27 1.34
Pivot Point 1.21 1.21 1.20 1.21 1.21
Support 1 (S1) 1.14 1.16 1.11 1.14 1.06
Support 2 (S2) 1.08 1.13 1.08 1.05
Support 3 (S3) 1.01 1.08 1.04
Support 4 (S4) 1.01